
|Articles|July 15, 2003
Posterior chamber phakic ICL a valuable option for moderate to high myopia
Author(s)Cheryl Guttman
San Francisco-Three-year FDA clinical trial outcome data support the safety, efficacy, and predictability of the Implantable Contact Lens (ICL, STAAR Surgical) for the treatment of moderate to high myopia, said Stephen G. Slade, MD, at the American Society of Cataract and Refractive Surgery annual meeting.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
Neurotrophic keratitis outcomes improve with early, stage-based care
3
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
4
Alcon raises offer in amended deal to acquire STAAR Surgical
5












































.png)


